BI
SPRO icon

BVF Inc’s Spero Therapeutics SPRO Stock Holding History

BVF Inc’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,929,376
Closed -$3.86M – 83
2022
Q3 		$3.86M Sell
1,929,376
-1,160,239
-38% -$1.15M 0.16% 62
2022
Q2 		$2.29M Buy
3,089,615
+1,504,000
+95% +$4.37M 0.11% 66
2022
Q1 		$13.8M Hold
1,585,615
– – 0.55% 51
2021
Q4 		$25.4M Sell
1,585,615
-223,737
-12% -$3.55M 0.92% 30
2021
Q3 		$33.3M Sell
1,809,352
-328,626
-15% -$5.27M 1.3% 21
2021
Q2 		$29.8M Hold
2,137,978
– – 1.12% 22
2021
Q1 		$31.5M Sell
2,137,978
-105,300
-5% -$1.85M 1.18% 24
2020
Q4 		$43.5M Buy
2,243,278
+898,944
+67% +$14M 1.71% 20
2020
Q3 		$15M Buy
1,344,334
+857,794
+176% +$10.1M 0.82% 36
2020
Q2 		$6.58M Sell
486,540
-76,853
-14% -$863K 0.41% 45
2020
Q1 		$4.55M Sell
563,393
-282,012
-33% -$2.49M 0.42% 41
2019
Q4 		$8.13M Sell
845,405
-94,299
-10% -$1.02M 0.62% 35
2019
Q3 		$9.96M Hold
939,704
– – 1.05% 28
2019
Q2 		$10.8M Buy
939,704
+478,998
+104% +$5.77M 1.18% 27
2019
Q1 		$5.9M Sell
460,706
-382,440
-45% -$4.06M 0.66% 40
2018
Q4 		$5.18M Sell
843,146
-644,942
-43% -$5.22M 0.68% 37
2018
Q3 		$15.6M Buy
1,488,088
+439,130
+42% +$5.1M 1.37% 25
2018
Q2 		$15.4M Hold
1,048,958
– – 1.5% 24
2018
Q1 		$14.9M Buy
1,048,958
+19,773
+2% +$240K 1.52% 20
2017
Q4 		$12.1M Buy
+1,029,185
New +$12.6M 1.46% 22

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc's SPRO Position: Q4 2022 in Review

BVF Inc sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 1,929,376 shares — an estimated $3.86M sold.

BVF Inc first reported a position in SPRO in Q4 2017 and held it in 20 quarters. The position peaked at $43.5M in Q4 2020. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • BVF Inc reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BVF Inc sold 1,929,376 Spero Therapeutics shares in Q4 2022, an estimated $3.86M.
  • BVF Inc first reported a position in Spero Therapeutics in Q4 2017 and held it in 20 quarters.
  • BVF Inc's Spero Therapeutics position peaked at $43.5M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.